The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs.
The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs.
Treatment options for gonorrhea are rare. repurposing bioactive molecule drugs approved for other conditions as it may be of value. We developed a method for wide-scale, systematic drug repurposing screen to identify molecules with activity against Neisseria gonorrhoeae and filtered Prestwick Chemical Library (1200 FDA-approved drugs). As the concept of evidence-, we further examined the promising and attractive screening hit (auranofin; antirheumatic agents). Three WHO gonococcal reference strains (WHO F, O, P) is used for library screening.
The strains were grown in the presence of a fixed concentration of the drug libraries in 384-well plates for 12 hours and the remaining bacterial respiration, to reflect the growth, then quantitatively measured using optical density (OD) of 450 nm and resazurin test. Auranofin activities further examined using in vitro susceptibility testing (minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)) against genetically diverse strains of N. gonorrhoeae antimicrobial-resistant and time-kill tests. Sixty-eight molecule significantly inhibited the growth of bacteria of the WHO F, O and P. auranofin showed potent in vitro bactericidal activity (in Mic, MBC-, and test time-kill) against four strains of the WHO reference.
There is no cross resistance between auranofin and any current or previous antimicrobials used for the treatment of gonorrhea are found when examining the 51 selected strains of gonococcal antimicrobial-resistant. In conclusion, this is the first systematic effort wide-scale screening for drug repurposing for the future treatment of gonorrhea.
Additional study the mechanism (s) of action, development of resistance to the examination, in vivo anti-gonococcal activity, and pharmacokinetics / pharmacodynamics for gonococcal infections of auranofin and other important hit some screening will be valuable.
The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs.
Drosophila Model SMN2 minigene reporter identified moxifloxacin as a therapeutic candidate for SMA.
Spinal muscular atrophy is a rare and fatal neuromuscular disorder that is caused by the loss of the alpha motor neuron. Affected individuals have mutated SMN1 gene that is ubiquitously expressed result in the loss or reduction in the protein content of the survival motor neuron (SMN). However, paralog almost identical in humans: SMN2. Pharmacological activation of SMN2 exon 7 inclusion by small molecules or modified antisense oligonucleotide is a valid approach to treating SMA.
Here we describe in vivo SMN2 minigene reporter system in Drosophila motor neurons to function as a primary screening model of cost-effective, feasible, and rigorous to identify chemicals that are able to cross the blood-brain barrier Drosophila conserved and modulation of exon 7 inclusion. This model is used to screen for drugs in 1100 from Prestwick Chemical Library, resulting in a 2.45% hit rate. The most promising candidates are validated drug in the patient-derived fibroblasts in which they are shown to increase SMN protein levels.
Among them, moxifloxacin modulated SMN2 exon 7 splicing by promoting inclusion. Recovery of SMN protein levels were confirmed by an increase in nuclear jewel colocalization with Cajal Agency. Thus, the Drosophila-based drug screen enables the discovery of small molecules that are FDA approved with the potential to become a new therapy for SMA. The incidence of severe infection filamentous fungi has been increasing over the last decade.
Description: A competitive ELISA for quantitative measurement of Rat Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Aspartate Aminotransferase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Some of these filamentous fungi resistant to antifungal available; so it is urgent to find new compounds that are active against pathogens such as life threatening. Here, in 1280 drugs (Prestwick Chemical Library) were tested against six multidrug-resistant filamentous fungi, including Aspergillus, Fusarium, Scedosporium, Rhizopus and Lichtheimia species.